Bicycle Therapeutics plc — Q2 2022 Form 10-Q
Business context and reporting period. Clinical-stage biopharmaceutical company developing its Bicycle peptide platform and oncology candidates. The filing covers the quarter and six months ended June 30, 2022, compared with the same 2021 periods. It has no approved products and generated no product-sales revenue; revenue came from collaborations.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Collaboration revenue | $4.4m | $1.8m | $8.2m | $3.6m |
| Research and development expense | $19.9m | $11.7m | $34.1m | $21.4m |
| General and administrative expense | $11.8m | $7.3m | $28.8m | $15.5m |
| Operating loss | $27.3m | $17.3m | $54.7m | $33.3m |
| Net loss | $26.8m | $17.9m | $54.4m | $34.1m |
| Net loss per share | $0.90 | $0.74 | $1.84 | $1.48 |
| Operating cash used | — | — | $49.9m | $26.1m |
| Capital expenditures | — | — | $14.6m | $0.8m |
At June 30, cash and cash equivalents were $372.8m, down from $438.7m at year-end 2021. Current assets were $408.5m and current liabilities $41.3m. The company reported $30.0m of outstanding loan principal ($30.1m carrying value); no principal was scheduled before 2024 under the terms then in effect. Deferred revenue was $66.4m. The filing does not provide a meaningful product gross margin, as the company has no product sales.
Changes versus the prior comparable periods
- Q2 collaboration revenue rose $2.6m; first-half revenue rose $4.6m, mainly reflecting Ionis collaboration revenue and AstraZeneca revenue recognized after termination of activities for one target.
- Operating expenses and losses increased substantially. Management attributed higher R&D costs to clinical and platform spending, increased headcount, share-based compensation and facilities. Higher G&A reflected compensation, public-company costs and foreign-exchange effects.
- First-half cash used in operations increased to $49.9m; property and equipment purchases rose to $14.6m, principally for laboratory equipment and leasehold improvements. Cash declined $65.9m overall.
- Genentech exercised its second expansion option in June, triggering a $10.0m payment; the amount was included in accounts receivable at quarter-end. AstraZeneca’s termination of a target caused $1.2m of previously deferred revenue to be recognized.
Outlook, commentary and risks
- Management expected cash to fund operating expenses and capital expenditure requirements for at least 12 months from the filing date, while warning that expenses are expected to rise and additional funding will be needed. The company expects continuing operating losses and cannot predict when, if ever, product revenue or profitability will occur.
- Pipeline programs include company-sponsored Phase I/II trials of BT5528, BT8009 and BT7480; BT1718 is in a Cancer Research UK-sponsored Phase I/IIa trial. Enrollment continued, including expansion cohorts for BT5528. Management reported earlier signs of anti-tumor activity for BT5528 and BT8009, but emphasized the uncertainty of early clinical results.
- On July 15, 2022, after quarter-end, the Hercules loan amendment capped the interest rate at 9.05%, extended the interest-only period to April 1, 2025 and maturity to July 1, 2025, and allowed requests for additional loans subject to conditions, up to $75m total principal by December 31, 2024.
- Key risks include clinical-trial failure or delay, patient enrollment, safety and regulatory uncertainty, reliance on collaborators and contract manufacturers, intellectual-property disputes, and the need for further capital. The filing also cites potential effects of COVID-19, the Russia-Ukraine war, foreign-exchange movements and global financial-market disruption.
- The company recorded a $3.3m long-term liability relating to the Cancer Research UK BT1718 arrangement. It disclosed no other material legal proceedings beyond an ongoing European patent opposition appeal scheduled for November 2022.
Most important facts for investors to verify
- Cash runway assumptions and the pace of cash use, especially as clinical programs and capital spending expand.
- Clinical-trial enrollment, safety and efficacy data for BT5528, BT8009 and BT7480, and progress of BT1718.
- Timing and terms of collaboration cash receipts, including collection of the $10.0m Genentech receivable and future contingent milestones.
- Impact of the revised Hercules loan terms, potential additional borrowing, and debt-related covenants and collateral.
- Whether collaboration revenue and available funding can keep pace with rising operating expenses before any product commercialization.